- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Johnson and Johnson (JNJ)
Find here information about Johnson & Johnson (JNJ) share price. You can find more details about Johnson & Johnson stock by going to one of the sections listed on this page such as historical data, price charts, JNJ stock technical analysis and more.
NYSE
Symbol | Exchange | Currency | |||
|---|---|---|---|---|---|
| JNJ | · | NYSE | · | USD | |
| JNJ | · | CBOE Canada | · | CAD | |
| JNJ | · | Toronto | · | CAD | |
| JNJ | · | Mexico | · | MXN | |
| 1JNJ | · | Milan | · | EUR | |
| JNJUSD | · | Switzerland | · | USD | |
| JNJ | · | Switzerland | · | CHF | |
| JNJ | · | TradeGate | · | EUR | |
| JNJ | · | Frankfurt | · | EUR | |
| JNJ | · | Xetra | · | EUR | |
| DJNJ2m | · | Buenos Aires | · | ARS | |
| JNJm | · | Buenos Aires | · | ARS | |
| DJNJ3m | · | Buenos Aires | · | ARS | |
| JNJB34 | · | B3 | · | BRL | |
| JNJ | · | Vienna | · | EUR | |
| JNJ | · | Ukraine | · | UAH | |
| JNJ_KZ | · | KASE | · | USD | |
| JNJ | · | Colombia | · | COP | |
| JNJ | · | Lima | · | USD |
Currency in USD
240.17
+2.21(+0.93%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
233.25
242.19
52 wk Range
146.12
251.71
Earnings results expected today
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
233.25242.19
52 wk Range
146.12251.71
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.15%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.15%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
JNJ Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
241.92
Upside
+0.73%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Johnson & Johnson SWOT Analysis
Oncology Powerhouse | Johnson & Johnson's oncology division emerges as a key growth driver, with CARVYKTI leading the charge and projections of $50 billion in oncology sales by 2030 |
Financial Resilience | Despite challenges, J&J reports robust Q4 2024 results with 5.9% adjusted operational sales growth, surpassing expectations and demonstrating financial stability |
Strategic Expansion | J&J explores CAR-T therapies beyond oncology, venturing into autoimmune diseases and strengthening its portfolio through strategic acquisitions like V-Wave |
Analyst Perspectives | Price targets range from $152 to $215, reflecting varied outlooks on J&J's growth potential amid ongoing talc litigation and upcoming Stelara biosimilar competition |
Johnson & Johnson Earnings Call Summary for Q1/2026
- Q1 2026 revenue hit $24.1B (up 6.4% YoY), beating estimates of $23.61B; adjusted EPS of $2.70 topped forecast of $2.68 by 0.75%
- Stelara sales plunged 61.7% due to biosimilar competition, creating major headwind; excluding Stelara, company posted double-digit growth
- Full-year guidance raised on strength in oncology/immunology portfolios and expected momentum from new product launches in MedTech
- Stock declined 0.5% in premarket to $236.78 despite earnings beat, reflecting investor concerns over biosimilar pressures on key products
- U.S. sales grew 8.3% vs international 3.9%; net earnings reached $5.2B as company navigates tariffs and regulatory challenges
Last Updated: 14/04/2026, 14:58
Read Full TranscriptCompare JNJ to Peers and Sector
Metrics to compare | JNJ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJNJPeersSector | |
|---|---|---|---|---|
P/E Ratio | 21.7x | 20.1x | −0.4x | |
PEG Ratio | 0.24 | 0.08 | 0.00 | |
Price/Book | 7.1x | 5.4x | 2.6x | |
Price / LTM Sales | 6.2x | 4.3x | 3.2x | |
Upside (Analyst Target) | 3.8% | 0.0% | 49.0% | |
Fair Value Upside | Unlock | 10.6% | 6.8% | Unlock |
Analyst Ratings
14 Buy
10 Hold
1 Sell
Ratings:
25 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 241.92
(+0.73% Upside)
Earnings
Latest Release
14/04/2026
EPS / Forecast
2.70 / 2.68
Revenue / Forecast
24.1B / 23.61B
People Also Watch
FAQ
What Is the J&J (JNJ) Share Price Today?
The J&J stock price today is 240.17 USD.
What Stock Exchange Does J&J (JNJ) Trade On?
J&J is listed and trades on the New York Stock Exchange.
What Is the Ticker (Stock Symbol) for J&J?
The stock symbol (also called a 'ticker') for J&J is "JNJ."
Does J&J Pay Dividends? What’s The Current JNJ Dividend Yield?
Yes, JNJ Pays Dividends to its Shareholders. The current J&J dividend yield is 2.15%.
What Is the Current J&J Market Cap?
As of today, J&J market cap is 578.79B USD.
What Is J&J's (JNJ) Earnings Per Share (TTM)?
The J&J EPS is currently 11.03 (Trailing Twelve Months).
When Is the Next J&J Earnings Date?
J&J's next earnings report will be released on 14/04/2026.
Is JNJ a Buy or Sell From a Technical Analyst Perspective?
Based on today's J&J moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has J&J Stock Split?
J&J has split 6 times. (See the JNJ stock split history page for full effective split date and price information.)
How Many Employees Does J&J Have?
J&J has 138200 employees.
What is the current trading status of J&J (JNJ)?
As of 14/04/2026, J&J (JNJ) is trading at a price of 240.17 USD, with a previous close of 237.96 USD. The stock has fluctuated within a day range of 233.25 USD to 242.19 USD, while its 52-week range spans from 146.12 USD to 251.71 USD.
What Is J&J (JNJ) Price Target According to Analysts?
The average 12-month price target for J&J is 241.92 USD, with a high estimate of 285 USD and a low estimate of 155 USD. 14 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +0.73% Upside potential.
What Is the JNJ Premarket Price?
JNJ's last pre-market stock price is 236.78 USD. The pre-market share volume is 309,580.00, and the stock has decreased by -1.18, or -0.50%.
What Is the JNJ After Hours Price?
JNJ's last after hours stock price is 237.80 USD, the stock has decreased by -0.16, or -0.07%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.